Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
82 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2017, provides an overview of the Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline landscape. Alpha-antitrypsin deficiency is an inherited disease that occurs due to lack of alpha-1 antitrypsin (AAT), a protein that protects the lungs. Symptoms include shortness of breath and wheezing, lung infections, rapid heartbeat, weight loss and vision problems. Predisposing factors include smoking, exposure to dust, chemical fumes and infections. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Alpha- Antitrypsin Deficiency (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Alpha- Antitrypsin Deficiency and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 1, 9 and 5 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively. Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Alpha- Antitrypsin Deficiency (Genetic Disorders). - The pipeline guide reviews pipeline therapeutics for Alpha- Antitrypsin Deficiency (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Alpha- Antitrypsin Deficiency (Genetic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Alpha- Antitrypsin Deficiency (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Alpha- Antitrypsin Deficiency (Genetic Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Alpha- Antitrypsin Deficiency (Genetic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Alpha- Antitrypsin Deficiency - Overview Alpha- Antitrypsin Deficiency - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Alpha- Antitrypsin Deficiency - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Alpha- Antitrypsin Deficiency - Companies Involved in Therapeutics Development Adverum Biotechnologies Inc Alnylam Pharmaceuticals Inc Apollo Therapeutics LLC Applied Genetic Technologies Corp Arrowhead Pharmaceuticals Inc Carolus Therapeutics Inc Cevec Pharmaceuticals GmbH Editas Medicine Inc Grifols SA Inhibrx LP Intellia Therapeutics Inc International Stem Cell Corp Ionis Pharmaceuticals Inc Kamada Ltd Polyphor Ltd ProMetic Life Sciences Inc rEVO Biologics Inc Alpha- Antitrypsin Deficiency - Drug Profiles ADVM-043 - Drug Profile Product Description Mechanism Of Action R&D Progress AGTC-0106 - Drug Profile Product Description Mechanism Of Action R&D Progress ALN-AAT - Drug Profile Product Description Mechanism Of Action R&D Progress ALNAAT-02 - Drug Profile Product Description Mechanism Of Action R&D Progress alpha-1 proteinase inhibitor (human) - Drug Profile Product Description Mechanism Of Action R&D Progress alpha-1 proteinase inhibitor (human) second generation - Drug Profile Product Description Mechanism Of Action R&D Progress ARO-AAT - Drug Profile Product Description Mechanism Of Action R&D Progress CT-2009 - Drug Profile Product Description Mechanism Of Action R&D Progress Drugs for Alpha-1 Antitrypsin Deficiency - Drug Profile Product Description Mechanism Of Action R&D Progress ISIS-AATRx - Drug Profile Product Description Mechanism Of Action R&D Progress Oligonucleotides to Activate Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency - Drug Profile Product Description Mechanism Of Action R&D Progress Oligonucleotides to Inhibit Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency - Drug Profile Product Description Mechanism Of Action R&D Progress POL-6014 - Drug Profile Product Description Mechanism Of Action R&D Progress rAAV2-CB-hAAT - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant A1PI - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Human Alpha-1 Antitrypsin - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Human Alpha-1 Antitrypsin Replacement for Alpha-Antitrypsin Deficiency - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein for Alpha-1 Antitrypsin Deficiency - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Alpha-1 Antitrypsin Deficiency - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Alpha-1 Antitrypsin Polymerization for Alpha-1 Antitrypsin Deficiency - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy for Alpha-Antitrypsin Deficiency, Crigler-Najjar Syndrome and Liver Cirrhosis - Drug Profile Product Description Mechanism Of Action R&D Progress Alpha- Antitrypsin Deficiency - Dormant Projects Alpha- Antitrypsin Deficiency - Discontinued Products Alpha- Antitrypsin Deficiency - Product Development Milestones Featured News & Press Releases Oct 14, 2016: Adverum Biotechnologies Provides Update on Alpha-1 Antitrypsin Deficiency Program Aug 30, 2016: Kamada Meets Primary Endpoint of U.S. Phase 2 Study of Inhaled Alpha-1 Antitrypsin for the Treatment of Alpha-1 Antitrypsin Deficiency May 05, 2016: Investigational Gene-Based Therapy for Alpha-1 Antitrypsin Deficiency Demonstrates Durable Response at Five Years Jan 20, 2016: AGTC Announces Data Evaluating Novel AAV-Based Gene Therapy as a Potential Treatment for Alpha-1 Antitrypsin Deficiency Dec 08, 2015: Kamada Completes Enrollment of U.S. Phase 2 Study of Inhaled Alpha-1 Antitrypsin for the Treatment of AAT Deficiency May 20, 2015: Kamada Reports Updated Data from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin to Treat AAT Deficiency Apr 20, 2015: Kamada Reports Additional Data from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin to Treat AAT Deficiency Jan 07, 2015: Kamada Reports Encouraging Discussions with European Co-Rapporteurs Regarding European Filing for Inhaled Alpha-1 Antitrypsin to Treat AATD Sep 04, 2014: Kamada Reports Final Results from Phase 2/3 Clinical Trial of Inhaled Alpha-1 Antitrypsin to Treat Alpha-1 Antitrypsin Deficiency Sep 03, 2014: Kamada to Announce Final Results from Phase 2/3 Clinical Trial of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency on September 4, 2014 May 16, 2014: Kamada Announces Preliminary Results from Phase II/III Pivotal Trial in Europe and Canada of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency May 15, 2014: Kamada to Announce Results from Phase 2/3 Clinical Trial of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency on May 16 Mar 24, 2014: Kamada Announces Initiation of a Phase 2 U.S. Clinical Trial of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency Mar 21, 2014: Kamada to Report Top-Line Data from Phase 2/3 Clinical Trial of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency by Late April or Early May Dec 11, 2013: Kamada Announces Completion of Pivotal Phase II/III Clinical Trial in Europe and Canada of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Alpha- Antitrypsin Deficiency, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Alpha- Antitrypsin Deficiency - Pipeline by Adverum Biotechnologies Inc, H1 2017 Alpha- Antitrypsin Deficiency - Pipeline by Alnylam Pharmaceuticals Inc, H1 2017 Alpha- Antitrypsin Deficiency - Pipeline by Apollo Therapeutics LLC, H1 2017 Alpha- Antitrypsin Deficiency - Pipeline by Applied Genetic Technologies Corp, H1 2017 Alpha- Antitrypsin Deficiency - Pipeline by Arrowhead Pharmaceuticals Inc, H1 2017 Alpha- Antitrypsin Deficiency - Pipeline by Carolus Therapeutics Inc, H1 2017 Alpha- Antitrypsin Deficiency - Pipeline by Cevec Pharmaceuticals GmbH, H1 2017 Alpha- Antitrypsin Deficiency - Pipeline by Editas Medicine Inc, H1 2017 Alpha- Antitrypsin Deficiency - Pipeline by Grifols SA, H1 2017 Alpha- Antitrypsin Deficiency - Pipeline by Inhibrx LP, H1 2017 Alpha- Antitrypsin Deficiency - Pipeline by Intellia Therapeutics Inc, H1 2017 Alpha- Antitrypsin Deficiency - Pipeline by International Stem Cell Corp, H1 2017 Alpha- Antitrypsin Deficiency - Pipeline by Ionis Pharmaceuticals Inc, H1 2017 Alpha- Antitrypsin Deficiency - Pipeline by Kamada Ltd, H1 2017 Alpha- Antitrypsin Deficiency - Pipeline by Polyphor Ltd, H1 2017 Alpha- Antitrypsin Deficiency - Pipeline by ProMetic Life Sciences Inc, H1 2017 Alpha- Antitrypsin Deficiency - Pipeline by rEVO Biologics Inc, H1 2017 Alpha- Antitrypsin Deficiency - Dormant Projects, H1 2017 Alpha- Antitrypsin Deficiency - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
